PanGen Biotech Inc. (KOSDAQ: 222110)
South Korea
· Delayed Price · Currency is KRW
5,640.00
+40.00 (0.71%)
Dec 19, 2024, 1:50 PM KST
PanGen Biotech Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Dec '24 Dec 18, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 72,746 | 73,462 | 69,405 | 99,783 | 97,864 | 74,917 | |
Market Cap Growth | -23.33% | 5.85% | -30.44% | 1.96% | 30.63% | -26.00% | |
Enterprise Value | 69,040 | 74,767 | 67,446 | 92,638 | 96,121 | 65,917 | |
Last Close Price | 5640.00 | 6880.00 | 6500.00 | 9350.00 | 10150.00 | 7770.00 | |
Forward PE | - | 91.30 | 91.30 | 91.30 | 91.30 | 91.30 | |
PS Ratio | 4.54 | 10.04 | 10.68 | 12.57 | 15.81 | 26.00 | |
PB Ratio | 3.57 | 5.85 | 4.03 | 4.73 | 6.89 | 4.07 | |
P/TBV Ratio | 2.71 | 6.29 | 4.09 | 4.80 | 7.02 | 4.13 | |
EV/Sales Ratio | 5.03 | 10.22 | 10.38 | 11.67 | 15.53 | 22.88 | |
Debt / Equity Ratio | 0.13 | 0.16 | 0.00 | 0.89 | 1.29 | 0.94 | |
Debt / EBITDA Ratio | 1.60 | - | - | - | - | - | |
Asset Turnover | 0.57 | 0.35 | 0.20 | 0.20 | 0.16 | 0.07 | |
Inventory Turnover | 1.17 | 0.94 | 1.06 | 1.82 | 2.12 | 7.79 | |
Quick Ratio | 1.63 | 0.42 | 1.55 | 1.28 | 0.97 | 1.30 | |
Current Ratio | 3.30 | 1.72 | 7.59 | 1.57 | 1.20 | 1.35 | |
Return on Equity (ROE) | -3.65% | -30.14% | -23.46% | -18.75% | -26.69% | -39.40% | |
Return on Assets (ROA) | -0.18% | -12.75% | -8.97% | -5.16% | -6.14% | -11.77% | |
Return on Capital (ROIC) | -0.23% | -16.61% | -10.06% | -5.68% | -6.76% | -12.64% | |
Earnings Yield | -1.02% | -6.11% | -6.47% | -3.32% | -4.45% | -11.93% | |
FCF Yield | 0.58% | -5.27% | -6.10% | -4.76% | -5.56% | -5.98% | |
Buyback Yield / Dilution | -3.61% | -0.03% | -4.47% | -6.02% | 0.04% | -0.16% | |
Total Shareholder Return | -3.61% | -0.03% | -4.47% | -6.02% | 0.04% | -0.16% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.